MEA Urinary Tract Infections Market

MEA Urinary Tract Infections Market Size (2024 to 2029)

The Urinary Tract Infections Market size in the Middle East and Africa is estimated to grow USD 735.54 million by 2029 from USD 709.98 million in 2024, growing at a CAGR of 0.71% during the forecast period.

The evolution of new technologies has been creating a wide range of opportunities for the market players; the major market players in the region are adopting highly automated instruments with the help of technology for better diagnosis advancement; However, the Technological advances in the healthcare sector and changing and improving the scenario for urinary testing are the key growth factors in the region. 

The geriatric population is more prone to various diseases, growing geriatric population in the region is expected to uplift the market growth. Additionally, the major companies in the region are launching an effective combination of drugs, which is more likely to show a positive impact on the growth of the urinary tract infections market in the MEA region. 

Diabetes and urological health issues are closely connected; diabetes results in UTIs and bladder issues. It can often make urologic conditions even worse because it can impact blood flow, nerves, and sensory functions in the body. However, a large population in the Middle East and African countries are affected by diabetes. With the increasing prevalence of diabetes and kidney stones, the number of cases of UTI increases, which increases the demand for drugs, thus, driving the global urinary tract infection market.

The urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections, and it is more common in women than men. Therefore, UTI is considered as one of the frequent causes of morbidity and mortality regionally. In addition, growing research and development activities of a novel class of antibiotics for urinary tract infections create new growth opportunities for the market. 

According to a study published in Advances in Urology 2018, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population, and it affects all age groups but occurs more frequently in men than in women within the age of 20–49 years. Moreover, approximately 7% of women and 13% of men will develop a kidney stone during a lifetime; therefore, with the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn increases the demand for drugs, thus, driving the global urinary tract infection therapeutics market.

The high cost associated with the research and studies is the major restraint for the growth of the urinalysis market, which can further impact the launch of new products in the urinalysis market. In addition, the lack of awareness about the prevalence of UTIs in developing and underdeveloped countries is also restraining the growth of the MEA urinary tract infections market.

This research report on the Middle East and Africa Urinary Tract Infections Market has been segmented and sub-segmented into the following categories:

By Type of Medication:

• Penicillin & Combinations 
  • Amoxicillin
  • Amoxicillin-Clavulanate Potassium combination
• Quinolones             
  • Ciprofloxacin
  • Levofloxacin
  • Norfloxacin
  • Nalidixic Acid
• Aminoglycoside-Antibodies             
  • Gentamicin
  • Amikacin
• Cephalosporin       
  • Ceftriaxone
  • Cefixime
  • Cefuroxime
  • Cephalexin
• Sulphonamides     
  • Sulfamethoxazole
  • Trimethoprim combination
• Azoles & Amphotericin B  
• Tetracycline            
  • Doxycycline
  • Nitrofurans
• Nitrofurans 

By Type of Indication:

• Uncomplicated UTI
• Complicated UTI   
• Recurring Complicated UTI               
• Neurogenic Bladder Infection 

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Regionally, the Middle East and African market are projected to account for a substantial share in the global Urinary Tract Infections Market during the forecast period. The market growth in the region is majorly attributed to the development of efficient and advanced technology, the growing prevalence of kidney diseases and urinary tract infections, and the rise in awareness among people regarding urinary tract infections. Also, increasing government initiatives across the region, rising investments, and funding by the government for healthcare infrastructure development further encourage market growth. As a result, the countries like Saudi Arabia, UAE, Egypt, and South Africa are significantly contributing and expanding the MEA regional market growth. In addition, the emergence of portable and battery-operated urinary tract infections devices and an increase in the adoption of urinary tract infections in emerging economies such as the United Arab Emirates, Saudi Arabia, South Africa, and others will create new opportunities for the urinary tract infections market. South Africa dominated the urinary tract infections market. Rising healthcare expenditures are the prime growth drivers of the urinary tract infections market.

KEY MARKET PLAYERS:

A few of the major market participants operating in the MEA Urinary Tract Infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.